Biotech RadarJobs updated

COMPANY

Cardurion Pharmaceuticals

HQ: Burlington, MA (US office) source · cardurion.com ↗ · New England

Clinical Phase 2

Keywords: cardiovascular cardiovascular disease rare disease catecholaminergic polymorphic ventricular tachycardia heart failure Cardiovascular Diseases Heart Diseases Sickle Cell Disease Heart Failure With Reduced Ejection Fraction Heart Failure With Preserved Ejection Fraction Heart Failure Preserved Ejection Fraction CPVT1 Congenital Heart Defects β Thalassemia Clinical Pharmacology Sickle Beta 0 Thalassemia CRD-4730 IMR-687 Tovinontrine (CRD-750) CRD-740

Location: Burlington, MA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

12Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $260M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Trial start Phase 2: A Trial of CRD-4730 in HFrEF source ↗
  2. Trial start 2: A Phase 2 Study of CRD-4730 in CPVT source ↗
  3. Raise Series B · $260M source ↗
  4. Trial start Phase 2: A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF) source ↗
  5. Trial start Phase 2: Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) source ↗
  6. Trial start Phase 2: Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) source ↗
  7. Trial start Phase 1: Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 source ↗
  8. Trial start Phase 2: Effectiveness of CRD-740 in Heart Failure source ↗
  9. Trial start Phase 2: A Study of IMR-687 in Subjects With Beta Thalassemia source ↗
  10. Trial start Phase 2: A Study of IMR-687 in Subjects With Sickle Cell Disease source ↗
  11. Trial start Phase 2: A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) source ↗
  12. Trial start Phase 1: A Study of IMR-687 in Healthy Adult Volunteers source ↗
  13. Trial start Phase 2: Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT06215911A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)Phase 2CompletedFeb 13, 2024Oct 10, 2025 (actual)
NCT06215586Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)Phase 2CompletedFeb 13, 2024Sep 2, 2025 (actual)
NCT07750873A Trial of CRD-4730 in HFrEFPhase 2RecruitingJul 15, 20262028-09 (estimated)
NCT06658899A Phase 2 Study of CRD-4730 in CPVT2RecruitingDec 1, 20252027-04 (estimated)
NCT06005428Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Phase 2TerminatedNov 7, 2023May 31, 2025 (actual)
NCT04474314A Study of IMR-687 in Subjects With Sickle Cell DiseasePhase 2TerminatedAug 13, 2020Mar 2, 2022 (actual)
NCT04411082A Study of IMR-687 in Subjects With Beta ThalassemiaPhase 2TerminatedOct 16, 2020Mar 11, 2022 (actual)
NCT03401112A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)Phase 2CompletedJan 26, 2018Aug 28, 2020 (actual)
NCT05437094Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740Phase 1CompletedJun 27, 2022Aug 3, 2022 (actual)
NCT05312021Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection FractionPhase 2Withdrawn2022-042023-09 (estimated)
NCT02998450A Study of IMR-687 in Healthy Adult VolunteersPhase 1CompletedOct 18, 2016Jul 8, 2017 (actual)
NCT05409183Effectiveness of CRD-740 in Heart FailurePhase 2TerminatedMay 26, 2022May 2, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback